版本:
中国

BRIEF-Spectrum Pharmaceuticals announces initiation of a phase 2 trial of Poziotinib

March 30 Spectrum Pharmaceuticals Inc

* Spectrum Pharmaceuticals announces initiation of a phase 2 trial of Poziotinib in non-small cell lung cancer patients with EGFR exon 20 insertion mutations

* Top-Line results are expected before year-end Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐